TrialJournal of the European Academy of Dermatology and Venereology : JEADV2022

The effect of risankizumab on achieving minimal clinically important differences in patient-reported outcomes in patients with psoriatic arthritis: results from KEEPsAKE 1 and 2.

L E Kristensen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.